Categories AlphaGraphs, Health Care

Infographic: Highlights from Gilead Sciences (GILD) Q2 2020 earnings

Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and earnings estimates for the quarter.

GILD shares fell over 2% immediately following the announcement. The stock has gained 11% since the beginning of this year.

GIlead sciences Q2 2020 earnings

Looking forward to listening to management/ analysts comments on Q2 results? Stay tuned here for Gilead Science Q2 2020 earnings call transcript

CEO Daniel O’Day said, “We are also making important progress with our pipeline. In addition to the critical work of advancing remdesivir, we have continued to strengthen our presence in immuno-oncology. This includes six immuno-oncology agreements this year and the recent FDA approval for TecartusTM in mantle cell lymphoma.”

Prior performance

[irp posts=”67604″]

____

Most Popular

SNAP Earnings: All you need to know about Snap’s Q2 2021 earnings results

Snap Inc. (NYSE: SNAP) reported second quarter 2021 earnings results today. Revenues increased 116% year-over-year to $982 million. Net loss amounted to $151.6 million, or $0.10 per share, compared to

TWTR Earnings: Twitter swings to profit in Q2 as revenues surge 74%; results beat

Microblogging platform Twitter, Inc. (NYSE: TWTR) Thursday reported a profit for the second quarter of fiscal 2021, compared to a loss last year. Both earnings and revenue came in above

Earnings Infographic: Intel (INTC) Q2 2021 profit, revenue beat estimates

Intel Corporation (NASDAQ: INTC) Thursday reported financial results for the second quarter of 2021. The revenue was reported at $19.6 billion compared to $19.7 billion in the previous year's second

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top